Brief: Pharma Mar and South Korea's Boryung Pharm sign licensing deal for Zepsyre

Boryung

07/11/2017 10:16

Nov 7 (Reuters) - PHARMA MAR SA  PHMR.MC : 
    * SIGNS LICENSING AGREEMENT WITH BORYUNG PHARM TO 
COMMERCIALIZE 
THE MARINE-DERIVED ANTICANCER DRUG ZEPSYR (LURBINECTEDIN), IF 
APPROVED, IN SOUTH KOREA 
    * TO RECEIVE A NON-DISCLOSED UPFRONT PAYMENT AND TO BE 
ELIGIBLE 
FOR ADDITIONAL REMUNERATIONS UPON ACHIEVING REGULATORY AND SALES 
MILESTONES 
    * TO RETAIN EXCLUSIVE PRODUCTION RIGHTS AND TO SELL THE 
PRODUCT TO 
BORYUNG PHARM FOR COMMERCIAL USE 
    * ZEPSYRE IS CURRENTLY IN LATE-STAGE CLINICAL DEVELOPMENT 
FOR 
PLATINUM-RESISTANT OVARIAN CANCER AND FOR SMALL-CELL LUNG CANCER 
 
     
 Source text: http://bit.ly/2yb7aqY 
     
 Further company coverage:  PHMR.MC   
    
 
 
 (Gdynia Newsroom) 
 ((Gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))